Glaxo: Integration underway - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Glaxo: Integration underway

Sep 14, 2001

The operational integration of Glaxo with SmithKline Pharma seems to be through before its proposed merger by FY03. The management structure of the company has also undergone a change in the recent past. In a bid to revive its sales growth, the company has initiated a major rejuvenation of its product portfolio to focus on high margin products and align itself with that of SmithKline Pharma. The integration of its portfolio with SmithKline is expected to create a complimentary basket of products. The operational savings emerging from the merger is also widely known by now. Whether the new company, GSK India actually benefits from these exercises remains a question which only time would answer. Meanwhile the markets seem to be adopting a wait and watch approach.

Glaxo regrouped all its brands under four main categories based on their profitability and future potential. These categories are Big Bets, Strategic, Bread & Butter and Tail end. Big Bets and Strategic products account for just 27% of sales but contribute around 42% of the total gross profits, reflecting premium margins commanded by these products. While the company intends to commit adequate resources for the first two categories, the bread and butter brands would receive support based on their potential to become strategic brands.

Glaxo- betting on strategic brands
Brand Category % to total sales Gross Margins (%)
Big Bets 15% 50-55%
Strategic products 12% 40-45%
Others 73% 15-25%

The company’s performance in terms of sales growth as well on the operating margin front has been quite volatile in last three years as shown in the chart below. Though sales growth is expected to remain flat in the near term, operating margins are expected to improve in FY03.

A merger with SmithKline’s portfolio would also help…
Except an overlap in vitamins segment, Glaxo’s product portfolio is complimentary with that of SmithKline Pharma. While Glaxo has strong presence in Vitamins and Dermatology segments, SmithKline Pharma is increasing its focus on vaccines segment. The merged entity would have a wider product portfolio across various therapeutic segments. A wider basket of products enables cross selling of products to the same set of doctors and physicians.

Particulars Glaxo SmithKline Pharma GSK
Market Share 5.7 1.3 7
No. of Products 200 48 248

The merger is also expected to create considerable operational cost savings. The cumulative cost savings are estimated in the range of Rs 470 m by FY03. The primary areas for cost savings would be bulk sourcing of raw materials, reduction in staff costs and shift from high cost manufacturing centers. The merger effect coupled with Glaxo’s focus on strategic brands is expected to result in operating margins improvement. The company has also launched several new products in last one year.

At the current market price of Rs 291, the stock is trading at 29 times its expected earnings for FY02. In the past, the stock used to command premium to its peers. However, the valuation premium has been shrinking in last one year due to slowdown in company’s performance.

The markets would be closely watching the results of current restructuring exercise and benefits emerging from operational synergies with SmithKline Pharma. In the long run however, the company’s growth would depend on the new parent’s commitment towards GSK India in terms of new product introductions. Though usual concerns over 100% subsidiary are subdued in case of Glaxo at this point of time, the parent company does have a subsidiary operating in India viz, SmithKline Beecham Asia Pvt. Ltd.

Equitymaster requests your view! Post a comment on "Glaxo: Integration underway ". Click here!


More Views on News

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 25, 2020 12:57 PM


  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks